GlassScriptPhysician profile
Tami Inbar
NPI 1588043814
$658.72
in general payments reported to CMS, 2019-2025
13 companies · $132 in 2025
The $132 reported for 2025 was more than what a typical Adolescent Medicine (Pediatrics) provider received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.88 · 2021: $95.20 · 2022: $116 · 2023: $153 · 2024: $147 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $432.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $222.46 | 2021-2025 | Gardasil 9, Vaxelis, M-M-R II |
| Cranial Technologies, INC | $95.95 | 2020-2024 | Doc Band |
| Sanofi Pasteur INC. | $69.70 | 2022-2024 | |
| Verrica Pharmaceuticals INC. | $40.01 | 2024-2025 | Ycanth |
| Pfizer INC. | $37.07 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $27.11 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $26.86 | 2025 | Neffy |
| Ultragenyx Pharmaceutical INC. | $26.14 | 2023 | Crysvita |
| Alk-Abello, INC | $24.90 | 2024 | Odactra, Grastek, Ragwitek |
| Abbott Laboratories | $23.39 | 2025 | Id Now Instrument |
| Sobi, INC | $22.39 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.36 | 2021 | |
| Cognoa, INC. | $20.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tami Inbar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.